Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles

Molecular Imaging

Volumn 10, Issue 1, 2011, Pages 69-77

  Park, James O ^a   Stephen, Zachary ^a   Sun, Conroy ^a   Veiseh, Omid ^a   Kievit, Forrest M ^a   Fang, Chen ^a   Leung, Matthew ^a   Mok, Hyejung ^a   Zhang, Miqin ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEXA FLUOR; CELL SURFACES; CONFOCAL FLUORESCENCE MICROSCOPY; DUAL-MODALITY IMAGING; GLYPICAN-3; HEPATOCELLULAR CARCINOMA; INTRA-OPERATIVE; LIVER CANCER CELLS; MONODISPERSE; MULTI-FUNCTIONAL NANOPARTICLES; NEAR-INFRARED FLUORESCENCE; NON-TARGETED; PRE-TREATMENT; PRIMARY LIVER CANCERS; PROTEOGLYCANS; QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION; RELAXIVITY; STREPTAVIDIN; SUPERPARAMAGNETIC IRON OXIDES; TUMOR TARGETING;

CELL MEMBRANES; DISEASES; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; GROWTH KINETICS; IRON OXIDES; LIVER; MONOCLONAL ANTIBODIES; NANOPARTICLES; POLYMERASE CHAIN REACTION; RESONANCE; SUPERPARAMAGNETISM; TUMORS; VISUALIZATION;

MAGNETIC RESONANCE IMAGING;

8 AMINOHEXYLAMINO CAMP; 8-AMINOHEXYLAMINO CAMP; CYCLIC AMP; DRUG DERIVATIVE; GLYPICAN; MONOCLONAL ANTIBODY; NANOPARTICLE; STREPTAVIDIN;

ARTICLE; CELL STRAIN HEPG2; CHEMISTRY; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; LIVER TUMOR; METABOLISM; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CYCLIC AMP; FLOW CYTOMETRY; GLYPICANS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; NANOTECHNOLOGY; STREPTAVIDIN;

EID: 79951917796     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2010.00048     Document Type: Article

References (41)

1. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010;30:3-16.
2. Ferenci P, Fried M, Labrecque D, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010;44:239-45.
3. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 2009;44 Suppl XIX:96-101.
4. Altekruse S, McGlynn K, Reichman M. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
5. Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-83.
6. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
7. Bruix J, Llovet J. Major achievements in hepatocellular carcinoma. Lancet 2009;373:614-6.
8. Massarweh N, Park J, Farjah F, et al. Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2010;210:441-8.
9. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
10. Ayyappan A, Jhaveri K. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther 2010;10:507-19.
11. Sangiovanni A, Manini M, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinomas in cirrhosis. Gut 2010;59: 638-44.
12. Silva M, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008;57:1592-6.
13. Saborido B, Díaz J, de Los Galanes S, et al. Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma? Transplant Proc 2005;37:3874-7. (Pubitemid 43015197)
14. Veiseh O, Sun C, Fang C, et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res 2009;69:6200-7.
15. Zhang Y, Sun C, Kohler N, et al. Self-assembled coatings on individual monodisperse magnetite nanoparticles for efficient intracellular uptake. Biomed Microdevices 2004;6:33-40. (Pubitemid 38324861)
16. Kievit F, Veiseh O, Bhattarai N, et al. PEI-PEG-chitosan copolymer coated iron oxide nanoparticles for safe gene delivery: synthesis, complexation, and transfection. Adv Funct Mater 2009;19:2244-51.
17. Ruoslahti E, Bhatia S, Sailor M. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2009;188:759-768.
18. Harris T, von Maltzahn G, Lord M, et al. Protease-triggered unveiling of bioactive nanoparticles. Small 2008;4:1307-12.
19. Moghimi S, Hunter A, Murray J. Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev 2001;53: 283-318. (Pubitemid 32476118)
20. Schipper M, Iyer G, Koh A, et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 2009;5:126-34.
21. Lee H, Lee E, Kim do K, et al. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc 2006;128:7383-9. (Pubitemid 43849141)
22. Chen J, Wu H, Han D, et al. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett 2006;231:169-75. (Pubitemid 43038727)
23. Liu P, Li Z, Zhu M, et al. Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma. J Mater Sci Mater Med 2010;21:551-6.
24. Kou G, Wang S, Cheng C, et al. Development of SM5-1- conjugated ultrasmall superparamagnetic iron oxide nanoparticles for hepatoma detection. Biochem Biophys Res Commun 2008;374: 192-7.
25. Kim T, Park I, Nah J, et al. Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier. Biomaterials 2004;25:3783-92. (Pubitemid 38327067)
26. Sharkey R, Cardillo T, Rossi E, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250-5. (Pubitemid 43093674)
27. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-34. (Pubitemid 46671186)
28. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996;12:241-7. (Pubitemid 26080081)
29. Hsu H, Cheng W, Lai P. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997;57:5179-84. (Pubitemid 27498138)
30. Capurro M, Wanless I, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97. (Pubitemid 36799110)
31. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25. (Pubitemid 36629398)
32. Capurro MI, Xiang YY, Lobe C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005;65:6245-54. (Pubitemid 40994410)
33. Ishiguro T, Sugimoto M, Kinoshita Y, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 2008;68:9832-8.
34. Fang C, Bhattarai N, Sun C, Zhang M. Functionalized nanoparticles with long-term stability in biological media. Small 2009;5: 1637-41.
35. Fang C, Zhang M. Multifunctional magnetic nanoparticles for medical imaging applications. J Mater Chem 2009;19:6258-66.
36. Mok H, Bae K, Ahn C, et al. PEGylated and MMP-2 specifically dePEGylated quantum dots: comparative evaluation of cellular uptake. Langmuir 2009;25:1645-50.
37. Kim B, Han G, Toley B, et al. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat Nanotechnol 2010;5: 465-72.
38. Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol 2006;25:1165-70. (Pubitemid 47538116)
39. Baumhoer D, Tornillo L, Stadlmann S, et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues. A tissue microarray analysis of 4387 tissue samples. Am J Clin Pathol 2008;129:899-906.
40. Fonseca M, Haisma H, Klaassen S, et al. Design of immunoenzysomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties. Biochim Biophys Acta 1999;1419:272-82. (Pubitemid 29322716)
41. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006;131:1758-67. (Pubitemid 46001394)